ARTICLE | Company News
Alnylam, Silence Therapeutics cancer news
December 12, 2011 8:00 AM UTC
Silence said the Opposition Division of the European Patent Office upheld an amended form of European Patent EP 1536827, which covers the use of protein kinase N (PKN) beta as a downstream target of t...